Literature DB >> 22129082

A review of neurobiological vulnerability factors and treatment implications for comorbid tobacco dependence in schizophrenia.

Victoria C Wing1, Caroline E Wass, Debra W Soh, Tony P George.   

Abstract

There is converging evidence that certain subpopulations of smokers, such as smokers with a serious mental illness like schizophrenia (SCZ), are more likely to become addicted to tobacco and are less likely to quit smoking. This review focuses on the unique risk factors that may increase vulnerability to the initiation and maintenance of nicotine addiction in persons with schizophrenia and other psychotic disorders and also reviews the latest approaches to treating nicotine addiction and schizophrenia based on our neurobiological understanding of central nicotinic receptor systems and related neurotransmitters. In addition, suggestions for future lines of research to better understand reasons for the comorbidity of nicotine addiction in schizophrenia are discussed.
© 2012 New York Academy of Sciences.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22129082     DOI: 10.1111/j.1749-6632.2011.06261.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  32 in total

1.  Toward a comprehensive developmental model of smoking initiation and nicotine dependence.

Authors:  Olaya García-Rodríguez; Carlos Blanco; Melanie M Wall; Shuai Wang; Chelsea J Jin; Kenneth S Kendler
Journal:  Drug Alcohol Depend       Date:  2014-09-16       Impact factor: 4.492

2.  Suppression of Methamphetamine Self-Administration by Ketamine Pre-treatment Is Absent in the Methylazoxymethanol (MAM) Rat Model of Schizophrenia.

Authors:  Jana Ruda-Kucerova; Zuzana Babinska; Tibor Stark; Vincenzo Micale
Journal:  Neurotox Res       Date:  2017-04-18       Impact factor: 3.911

Review 3.  High-affinity nicotinic acetylcholine receptor expression and trafficking abnormalities in psychiatric illness.

Authors:  Alan S Lewis; Marina R Picciotto
Journal:  Psychopharmacology (Berl)       Date:  2013-04-28       Impact factor: 4.530

4.  Cognitive effects of very low nicotine content cigarettes, with and without nicotine replacement, in smokers with schizophrenia and controls.

Authors:  Christopher G AhnAllen; L Cinnamon Bidwell; Jennifer W Tidey
Journal:  Nicotine Tob Res       Date:  2014-08-20       Impact factor: 4.244

5.  Pharmacotherapy for smoking cessation in schizophrenia: a systematic review.

Authors:  Karolina Kozak; Tony P George
Journal:  Expert Opin Pharmacother       Date:  2020-02-03       Impact factor: 3.889

6.  Attention-enhancing effects of propranolol and synergistic effects with nicotine.

Authors:  Britta Hahn; Cory K Olmstead; Marie B Yuille; Joshua J Chiappelli; Ashleigh K Wells
Journal:  Cogn Affect Behav Neurosci       Date:  2020-06       Impact factor: 3.282

Review 7.  Treatment of tobacco dependence in people with mental health and addictive disorders.

Authors:  Kristen M Mackowick; Marie-Josee Lynch; Andrea H Weinberger; Tony P George
Journal:  Curr Psychiatry Rep       Date:  2012-10       Impact factor: 5.285

8.  A test of the cognitive-enhancing potential of low-dose mecamylamine in healthy non-smokers.

Authors:  Marie B Yuille; Cory K Olmstead; Ashleigh K Wells; Britta Hahn
Journal:  Psychopharmacology (Berl)       Date:  2016-09-27       Impact factor: 4.530

9.  Smoking Topography Characteristics of Very Low Nicotine Content Cigarettes, With and Without Nicotine Replacement, in Smokers With Schizophrenia and Controls.

Authors:  Jennifer W Tidey; Rachel N Cassidy; Mollie E Miller
Journal:  Nicotine Tob Res       Date:  2016-03-19       Impact factor: 4.244

Review 10.  Neurocognitive endophenotypes in schizophrenia: modulation by nicotinic receptor systems.

Authors:  Kristen M Mackowick; Mera S Barr; Victoria C Wing; Rachel A Rabin; Clairelaine Ouellet-Plamondon; Tony P George
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-07-19       Impact factor: 5.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.